kth.sePublications KTH
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
On data-driven affinity proteomics analysis
KTH, Centres, Science for Life Laboratory, SciLifeLab. KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Protein Science, Biomedical proteomics.ORCID iD: 0000-0003-1492-3052
2026 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Proteins are diverse biological macromolecules that play essential roles in many biological functions. The study of proteins has led to important biological and medical discoveries. With the advancement of technology, an increasing number of proteins can be measured in a single experiment. Today, from just a drop of blood, we can measure hundreds or thousands of proteins in the study of proteomes. This field of study is called proteomics and allows us to survey the vast array of proteins in our bodies to discover biological relationships that can improve our understanding of health and disease.

As the number of proteins that we can measure increases, so does the burden of analysing the increasingly large data sets. Data analysis pipelines must be crafted with care at every step, from data preprocessing to analysis, visualisation, and presentation. This thesis presents studies that showcase how one may go about interacting with large affinity proteomics data sets. 

To study the proteome we must be able to reliably measure proteins. Antibodies are used heavily in affinity proteomics for their excellent sensitivity. Their selectivity, however, must be validated thoroughly to ensure that we are measuring the correct protein. In study A, we validate antibodies targeting a clinically important family of proteins. The results have been published in an interactive web application open for anyone to browse.

The type of biological sample we use influences what proteins are present and what research questions we can answer. Blood is a practical sample type for its minimal invasiveness and its ability to provide a systemic view of an individual’s health. Dried blood spots (DBS) can be used as an alternative to venous blood draws that may also be performed without medical expertise, allowing remote self-sampling. In study B we perform a population study during the COVID-19 pandemic using DBS and demonstrate the feasibility of the sampling method for population proteomics. Study C expands on the previous study, establishing a general pipeline for immune phenotype exploration. These studies demonstrate the utility of the sampling and data analysis methods for profiling immune phenotypes through serology and proteomics. In study D we explore the biological differences between DBS and blood plasma in a large proteome survey using multiple proteomics technologies. Together, these studies provide insights into the dried blood proteome and how such data may be processed and analysed.

While the full breadth of proteomics and the analysis of such data cannot be captured in this one thesis, the work presented herein provides important contributions toward the reproducible analysis of large-scale affinity proteomics data.

Abstract [sv]

Proteiner är mångfaldiga biologiska makromolekyler som spelar en livsviktig roll i många biologiska funktioner. Forskning på proteiner har lett till viktiga biologiska och medicinska upptäckter. Utveckling av teknologi har gjort att fler och fler proteiner kan mätas i ett enda experiment. Idag kan vi mäta hundratals eller tusentals av proteiner från en droppe blod för att studera proteom. Detta forskningsfält kallas proteomik och låter oss undersöka de stora mängderna proteiner som finns i våra kroppar för att upptäcka biologiska samband som kan förbättra vår förståelse av hälsa och sjukdom. 

Allteftersom antalet proteiner som vi kan mäta ökar, ökar bördan av att analysera de växande mängderna av data. Dataanalysflöden måste skapas med omsorg i varje steg, från förbehandling av data till analys, visualisering, och presentation. Denna avhandling presenterar forskningsstudier som visar hur vi kan interagera med stora dataset från affinitetsproteomik. 

För att studera proteom måste vi kunna mäta proteiner pålitligt. Antikroppar används flitigt inom affinitetsproteomik för deras utmärkta känslighet. Dock måste deras urskiljningsförmåga kontrolleras för att säkerställa att vi mäter rätt proteiner. I studie A validerar vi antikroppar mot en kliniskt viktig familj av proteiner. Resultaten har publicerats i en interaktiv webbapplikation som är öppen för alla att utforska. 

Sorten av biologiskt prov påverkar vilka proteiner vi kan mäta och vilka forskningsfrågor vi kan besvara. Blodprov är praktiska eftersom de är minimalt invasiva och ger en systemisk bild av en individs hälsotillstånd. Torkade blodfläckar (dried blood spots, DBS) kan användas som ett alternativ till venös provtagning som även kan genomföras utan medicinsk expertis, vilket möjliggör självprovtagning på distans. I studie B genomför vi en populationsstudie under COVID-19-pandemin med hjälp av DBS och påvisar rimligheten av provtagningsmetoden för populationsproteomik. Studie C utvecklar den förra studien och etablerar ett generellt arbetsflöde för att utforska immunfenotyper. Dessa studier demostrerar användbarheten av provtagningen och analysmetoderna för profilering av immunfenotyper med hjälp av serologi och proteomik. I studie D utforskar vi de biologiska skillnaderna mellan DBS och blodplasma i en stor kartläggning av proteom genom att använda flera proteomikteknologier. Sammantagna bidrar dessa studier med inblickar i torrblodsproteomet och hur sådana data kan behandlas och analyseras.

Denna enskilda avhandling kan inte täcka hela vidden av proteomik och analysen av sådan data. Dock innehåller arbetena i denna avhandling viktiga bidraganden för reproducerbar analys av storskalig affinitetsproteomikdata.

Place, publisher, year, edition, pages
KTH Royal Institute of Technology, 2026. , p. 101
Series
TRITA-CBH-FOU ; 2026:14
National Category
Bioinformatics and Computational Biology Medical Biotechnology
Research subject
Biotechnology
Identifiers
URN: urn:nbn:se:kth:diva-381452ISBN: 978-91-8106-643-2 (print)OAI: oai:DiVA.org:kth-381452DiVA, id: diva2:2060784
Public defence
2026-06-12, Air & Fire, via Zoom: https://kth-se.zoom.us/j/61953580734, Tomtebodavägen 23A, Stockholm, 09:00 (English)
Opponent
Supervisors
Note

QC 2026-05-19

Available from: 2026-05-19 Created: 2026-05-19 Last updated: 2026-05-25Bibliographically approved
List of papers
1. Multiplexed selectivity screening of anti-GPCR antibodies
Open this publication in new window or tab >>Multiplexed selectivity screening of anti-GPCR antibodies
Show others...
2023 (English)In: Science Advances, E-ISSN 2375-2548, Vol. 9, no 18, article id eadf9297Article in journal (Refereed) Published
Abstract [en]

G protein-coupled receptors (GPCRs) control critical cellular signaling pathways. Therapeutic agents including anti-GPCR antibodies (Abs) are being developed to modulate GPCR function. However, validating the selectivity of anti-GPCR Abs is challenging because of sequence similarities among individual receptors within GPCR sub-families. To address this challenge, we developed a multiplexed immunoassay to test >400 anti-GPCR Abs from the Human Protein Atlas targeting a customized library of 215 expressed and solubilized GPCRs representing all GPCR subfamilies. We found that-61% of Abs tested were selective for their intended target,-11% bound off -target, and-28% did not bind to any GPCR. Antigens of on-target Abs were, on average, significantly longer, more disordered, and less likely to be buried in the interior of the GPCR protein than the other Abs. These results provide important insights into the immunogenicity of GPCR epitopes and form a basis for designing therapeu-tic Abs and for detecting pathological auto-Abs against GPCRs.

Place, publisher, year, edition, pages
American Association for the Advancement of Science (AAAS), 2023
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
urn:nbn:se:kth:diva-329863 (URN)10.1126/sciadv.adf9297 (DOI)000988274400002 ()37134173 (PubMedID)2-s2.0-85159546484 (Scopus ID)
Note

QC 20230626

Available from: 2023-06-26 Created: 2023-06-26 Last updated: 2026-05-19Bibliographically approved
2. Proteome profiling of home-sampled dried blood spots reveals proteins of SARS-CoV-2 infections
Open this publication in new window or tab >>Proteome profiling of home-sampled dried blood spots reveals proteins of SARS-CoV-2 infections
Show others...
2024 (English)In: Communications Medicine, E-ISSN 2730-664X, Vol. 4, no 1, article id 55Article in journal (Refereed) Published
Abstract [en]

Background Self-sampling of dried blood spots (DBS) offers new routes to gather valuable health-related information from the general population. Yet, the utility of using deep proteome profiling from home-sampled DBS to obtain clinically relevant insights about SARS-CoV-2 infections remains largely unexplored.Methods Our study involved 228 individuals from the general Swedish population who used a volumetric DBS sampling device and completed questionnaires at home during spring 2020 and summer 2021. Using multi-analyte COVID-19 serology, we stratified the donors by their response phenotypes, divided them into three study sets, and analyzed 276 proteins by proximity extension assays (PEA). After normalizing the data to account for variances in layman-collected samples, we investigated the association of DBS proteomes with serology and self-reported information.Results Our three studies display highly consistent variance of protein levels and share associations of proteins with sex (e.g., MMP3) and age (e.g., GDF-15). Studying seropositive (IgG+) and seronegative (IgG-) donors from the first pandemic wave reveals a network of proteins reflecting immunity, inflammation, coagulation, and stress response. A comparison of the early-infection phase (IgM+IgG-) with the post-infection phase (IgM-IgG+) indicates several proteins from the respiratory system. In DBS from the later pandemic wave, we find that levels of a virus receptor on B-cells differ between seropositive (IgG+) and seronegative (IgG-) donors.Conclusions Proteome analysis of volumetric self-sampled DBS facilitates precise analysis of clinically relevant proteins, including those secreted into the circulation or found on blood cells, augmenting previous COVID-19 reports with clinical blood collections. Our population surveys support the usefulness of DBS, underscoring the role of timing the sample collection to complement clinical and precision health monitoring initiatives. The COVID-19 pandemic has posed multiple challenges to healthcare systems. A significant gap that remains is a lack of understanding of the impact of SARS-CoV-2 on individuals who did not seek or require hospitalization. To address this, we distribute self-sampling devices to random citizens, aiming to analyze how blood protein levels are affected in people who have had COVID-19 but had no or mild symptoms. Conducting multiple molecular measurements in dried blood, our study confirms clinically known markers and their relationship to infection stages, even if the donors themselves collect the sample. Our work highlights the potential of combining self-sampling with laboratory methods to provide useful information on human health. This convenient patient-centric sampling approach may potentially be useful when studying other diseases. Fredolini et al. present a proteomics analysis of home-sampled dried blood spots taken from the general population in Stockholm during the COVID-19 pandemic. The study provides insights into the molecular effects of SARS-CoV-2 infection in non-hospitalized individuals and demonstrates the compatibility of self-sampled blood spots with proteomics.

Place, publisher, year, edition, pages
Springer Nature, 2024
National Category
Infectious Medicine Microbiology in the medical area
Identifiers
urn:nbn:se:kth:diva-345934 (URN)10.1038/s43856-024-00480-4 (DOI)001196972300001 ()38565620 (PubMedID)2-s2.0-85203675445 (Scopus ID)
Note

QC 20240426

Available from: 2024-04-26 Created: 2024-04-26 Last updated: 2026-05-19Bibliographically approved
3. Exploration of immune phenotypes in self-sampling citizens
Open this publication in new window or tab >>Exploration of immune phenotypes in self-sampling citizens
Show others...
2026 (English)In: iScience, E-ISSN 2589-0042, Vol. 29, no 2, article id 114611Article in journal (Refereed) Published
Abstract [en]

Blood proteins have provided essential insights into how humans responded to the recent pandemic. To expand our understanding beyond patients seeking medical care, we conducted a citizen-centric survey with 2,000 random residents (age: 18–69 years) from Sweden's two largest cities in 2021. With self-sampled dried blood spots (DBS) and health information from 437 (22%) volunteers, we performed multi-analyte COVID-19 serology, measured autoantibodies (AAbs) against 22 interferons, and quantified 502 circulating low-abundant immune-related blood proteins. Antibody assays confirmed self-reported infections (26%) and vaccinations (40%), showed timing-dependent discrepancies in the immune response, and revealed anti-type I interferon AAbs co-occurring frequently alongside natural infections. Proteomics data added plausible mechanistic insights into cell-mediated processes: data-driven analyses revealed 24% of participants presented deviating immune phenotypes linked to infections, immunity, respiratory effects, and age. Multi-molecular DBS analysis of random layperson samples captured the broader spectrum of immune system states, adding relevant insights for clinical and public health investigations.

Place, publisher, year, edition, pages
Elsevier BV, 2026
Keywords
Health sciences
National Category
Clinical Medicine
Identifiers
urn:nbn:se:kth:diva-376429 (URN)10.1016/j.isci.2025.114611 (DOI)001678914400001 ()41630906 (PubMedID)2-s2.0-105027974969 (Scopus ID)
Note

QC 20260206

Available from: 2026-02-06 Created: 2026-02-06 Last updated: 2026-05-29Bibliographically approved
4. An atlas of the human dried blood proteome
Open this publication in new window or tab >>An atlas of the human dried blood proteome
Show others...
(English)Manuscript (preprint) (Other academic)
National Category
Medical Biotechnology
Research subject
Biotechnology
Identifiers
urn:nbn:se:kth:diva-381446 (URN)
Note

QC 20260525

Available from: 2026-05-18 Created: 2026-05-18 Last updated: 2026-05-25Bibliographically approved

Open Access in DiVA

summary(10360 kB)70 downloads
File information
File name SUMMARY01.pdfFile size 10360 kBChecksum SHA-512
74abf28f1f0eaf986034dd9734b2ea6be4039a75d204d58671bd7c25a998f2116c4eed91cd79d83a71aacfa22097f2dfd7afe59de58e932521ee87c6aecc82aa
Type summaryMimetype application/pdf

Authority records

Dahl, Leo

Search in DiVA

By author/editor
Dahl, Leo
By organisation
Science for Life Laboratory, SciLifeLabBiomedical proteomics
Bioinformatics and Computational BiologyMedical Biotechnology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

isbn
urn-nbn

Altmetric score

isbn
urn-nbn
Total: 376 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf